digestVidSign in
summary

Drug Chug - How do GLP-1 Agonists Work? (EASY Pharmacology)

Thumbnail of the video “Drug Chug - How do GLP-1 Agonists Work? (EASY Pharmacology)”
Community upload. AI output has not been independently verified.
Author: Drug Chug
Categories: Health Nutrition
Tags: health, nutrition
Views: 1 · Last viewed: 2026-10-13 23:16 UTC

Short Summary

Main recommendation: GLP-1 agonists, such as semaglutide (Ozempic, Wegovy, Rybelsus), are used mainly for type 2 diabetes and weight loss by mimicking the natural incretin GLP-1, which lowers blood glucose and slows gastric emptying. They are typically injected subcutaneously, and the video explains dosing, kidney considerations, and key side effects and interactions.

Key Points

  • GLP-1 (glucagon-like peptide-1) is a hormone your body naturally produces after eating; "agonist" means a drug that activates its effects, and the names of these drugs typically end in "glutide" or "tide."
  • After a meal, GLP-1 and GIP incretins delay gastric emptying, increase pancreatic insulin release, and decrease liver glucagon, all of which lower blood glucose.
  • Injected GLP-1 agonists deliver these effects without needing a meal, and delayed gastric emptying is what makes patients feel full longer, supporting weight loss.
  • GLP-1 agonists are not first-line for type 2 diabetes; metformin is reserved for first line, and these drugs are added as second or third line. They are not used for type 1 diabetes.
  • Common side effects include nausea and GI upset (usually improving over time), weight loss, hypoglycemia, and rarely pancreatitis.

Details Worth Noting

Concrete instructions:

  • Semaglutide (Ozempic, Wegovy): 0.25 mg weekly for the first four weeks, then 0.5 mg weekly, titrated slowly up to a maximum of 2 mg weekly.
  • Rybelsus (semaglutide) is the only oral GLP-1 agonist mentioned; the rest are injectable.
  • Exenatide (Byetta, Bydureon): 5 mcg twice daily, up to 10 mcg twice daily, or the extended form of 2 mg once weekly.
  • Liraglutide (Victoza, Saxenda): 0.6 mg daily for one week, then 1.2 mg daily, up to 1.8 mg daily.
  • Tirzepatide (Mounjaro, Zepbound), a GLP-1 and GIP agonist: 2.5 mg weekly for four weeks, then 5 mg weekly, titrated weekly up to 15 mg weekly.
  • Warn patients in advance that nausea is likely when starting; it varies by person but nearly all experience some GI upset.
  • Do not use exenatide if GFR is below 30 (per the label); most other GLP-1 agonists do not need renal dose adjustment.
  • Do not combine a GLP-1 agonist with a DPP-4 inhibitor such as sitagliptin, because DPP-4 inhibitors block GLP-1 breakdown, causing excessive GLP-1 activity and a larger side-effect profile.
  • Watch for hypoglycemia, since these drugs stimulate insulin release through the pancreas.
  • Dosing frequency matters for adherence: exenatide's twice-daily schedule is described as unfavorable compared with weekly options.

Bottom Line

GLP-1 agonists lower blood sugar and curb appetite by extending the effects of GLP-1, so clinicians need to manage nausea, dosing schedules, kidney function, and the DPP-4 inhibitor interaction. This is an educational summary of what the video says, not professional medical advice.